Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Moodys
Johnson and Johnson
AstraZeneca
Accenture
Fish and Richardson
McKesson
QuintilesIMS

Generated: April 24, 2018

DrugPatentWatch Database Preview

ATROVENT Drug Profile

« Back to Dashboard

When do Atrovent patents expire, and what generic alternatives are available?

Atrovent is a drug marketed by Boehringer Ingelheim and is included in five NDAs. There are three patents protecting this drug.

The generic ingredient in ATROVENT is ipratropium bromide. There are eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
Drug patent expirations by year for ATROVENT
Pharmacology for ATROVENT
Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists
Medical Subject Heading (MeSH) Categories for ATROVENT
Synonyms for ATROVENT
(1R,5S)-3-((3-hydroxy-2-phenylpropanoyl)oxy)-8-isopropyl-8-methyl-8-azabicyclo[3.2.1]octan-8-ium bromide
(1R,5S)-3-[(3-HYDROXY-2-PHENYLPROPANOYL)OXY]-8-ISOPROPYL-8-METHYL-8-AZABICYCLO[3.2.1]OCTAN-8-IUM BROMIDE
(1S,3S,5R)-3-Tropyloxy-8-isopropyltropanium bromide
(3-Endo,8-anti)-3-((3-hydroxy-2-phenylpropanoyl)oxy)-8-isopropyl-8-methyl-8-azabicyclo[3.2.1]octan-8-ium bromide
(3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane bromide
(8r)-3-alpha-Hydroxy-8-isopropyl-1-alpha-H,5-alpha-H-tropiumbromide-(+-)-tropate
(endo,Anti)-(1)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-isopropyl-8-methyl-8-azoniabicyclo(3.2.1)octane bromide
(endo,syn)-(+-)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
(endo,syn)-(+/-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
(exo,Syn)-(1)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-isopropyl-8-methyl-8-azoniabicyclo(3.2.1)octane bromide
1-alpha-H,5-alpha-H-Tropanium, 3-alpha-hydroxy-8-isopropyl-, bromide, (+-)-tropate
22254-24-6
22254-36-0
24358-20-1
3-alpha-Hydroxy-8-isopropyl-1-alpha-H,5-alpha-H-tropanium bromide (+-)-tropate
3alpha-hydroxy-8-isopropyl-1alphaH,5alphaH-tropanium bromide (+-)-tropate
3alpha-hydroxy-8-isopropyl-1alphaH,5alphaH-tropanium bromide (+/-)-tropate
58073-59-9
60205-81-4 (Parent)
60251-88-9
8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, endo-
8-Isopropylnoratropine methobromide
AK110411
AK277771
AKOS015895324
AKOS016013651
AKOS027301349
AKOS030485952
ATEM
ATROPINE ISOPROPYLBROMIDE
Atrovent Hfa
BC677124
BDBM50021892
Bromure d'ipratropium
Bromure d'ipratropium [INN-French]
Bromuro de ipratropio
Bromuro de ipratropio [INN-Spanish]
C20H30BrNO3
CHEBI:46659
CHEMBL1464005
DB00332
DR002476
DTXSID60858923
EINECS 244-873-8
EINECS 246-197-9
EINECS 261-098-0
EINECS 262-128-5
HE326281
HMS2234J05
Ipatropium Bromide
Ipratropii bromidum
Ipratropii bromidum [INN-Latin]
ipratropium bromide
Ipratropium Bromide (anhydrous)
Ipratropium bromide [INN]
Ipratropium bromide anhydrous
Ipratropium bromide monohydrate
Ipratropiumbromid
Ipratropiumbromid [German]
Ipratropiumbromide
Itrop
MFCD00069291
MLS000069557
MolPort-006-069-092
MolPort-027-946-829
MolPort-035-924-120
N-Isopropylnoratropinium bromomethylate
N-Isopropylnortropine tropate methobromide
Opera_ID_1621
Prestwick_279
REGID_for_CID_657308
SC-14062
Sch 1000
SCHEMBL107906
SCHEMBL16762661
SCHEMBL3852
SCHEMBL3854
SMR000058764
ST51052817
UNII-VJV4X1P2Z1

US Patents and Regulatory Information for ATROVENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim ATROVENT ipratropium bromide AEROSOL, METERED;INHALATION 019085-001 Dec 29, 1986 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Boehringer Ingelheim ATROVENT ipratropium bromide SPRAY, METERED;NASAL 020394-001 Oct 20, 1995 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim ATROVENT ipratropium bromide SOLUTION;INHALATION 020228-001 Sep 29, 1993 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ATROVENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim ATROVENT ipratropium bromide SPRAY, METERED;NASAL 020394-001 Oct 20, 1995 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim ATROVENT ipratropium bromide AEROSOL, METERED;INHALATION 019085-001 Dec 29, 1986 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim ATROVENT ipratropium bromide SPRAY, METERED;NASAL 020393-001 Oct 20, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
McKinsey
Medtronic
Johnson and Johnson
Fish and Richardson
Cantor Fitzgerald
Citi
Mallinckrodt
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.